Title:
抗ＣＴＬＡ－４抗体およびその使用
Document Type and Number:
Japanese Patent JP7296363
Kind Code:
B2
Abstract:
The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.
Inventors:
Einer Harman
Ella Ioffe
Elena Brova
Gavin Thurston
William Olson
Ella Ioffe
Elena Brova
Gavin Thurston
William Olson
Application Number:
JP2020503984A
Publication Date:
June 22, 2023
Filing Date:
July 26, 2018
Export Citation:
Assignee:
REGENERON PHARMACEUTICALS, INC.
International Classes:
C12N15/13; A61K39/395; A61P35/00; C07K16/28; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/63; C12P21/08
Domestic Patent References:
| JP2002537226A | ||||
| JP2014512809A |
Foreign References:
| WO2009100140A1 | ||||
| WO2016130986A1 | ||||
| WO2017084078A1 | ||||
| WO2018107178A1 | ||||
| WO2016196237A1 |
Other References:
Ribas, A. et al.,Tremelimumab (CP-675, 206), a cytotoxic T lymphocyte-associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer,The Oncologist,2007年,12,873-883
Hodi, F. S. et al,Improved survival with ipilimumab in patients with metastatic melanoma,N Engl J Med.,2010年,363;8,711-723
Kirkwood, J. M. et al.,Phase II trial of tremelimumab (CP-675, 206) in patients with advanced refractory or relapsed melanoma,Clin Cancer Res.,2010年,16(3),1042-1048
Larkin, J. et al.,Combined nivolmab and ipilimumab or monotherapy in untreated melanoma,N Engl J Med.,2015年,373;1,23-34
Funt, S. A. et al.,CTLA-4 antibodies: new directions, new combinations,Oncology,2014年,28(3),1-14
Burova, E. et al.,Abstract 3824: Antitumor activity of REGN4659, a fully human anti-CTLA-4 monoclonal antibody, against MC38.Ova tumors grown in immunocompetent humanh CTLA-4 knoc-in mice,Cancer Res,2018年07月01日,78(13_Supplement)
Hodi, F. S. et al,Improved survival with ipilimumab in patients with metastatic melanoma,N Engl J Med.,2010年,363;8,711-723
Kirkwood, J. M. et al.,Phase II trial of tremelimumab (CP-675, 206) in patients with advanced refractory or relapsed melanoma,Clin Cancer Res.,2010年,16(3),1042-1048
Larkin, J. et al.,Combined nivolmab and ipilimumab or monotherapy in untreated melanoma,N Engl J Med.,2015年,373;1,23-34
Funt, S. A. et al.,CTLA-4 antibodies: new directions, new combinations,Oncology,2014年,28(3),1-14
Burova, E. et al.,Abstract 3824: Antitumor activity of REGN4659, a fully human anti-CTLA-4 monoclonal antibody, against MC38.Ova tumors grown in immunocompetent humanh CTLA-4 knoc-in mice,Cancer Res,2018年07月01日,78(13_Supplement)
Attorney, Agent or Firm:
Junji Yuda
Noriyuki Takebayashi
Noriyuki Takebayashi
Previous Patent: Method and apparatus for the production of hydrogen
Next Patent: MAGNETIC RECORDING MEDIUM AND RECORDING/REPRODUCING METHOD
Next Patent: MAGNETIC RECORDING MEDIUM AND RECORDING/REPRODUCING METHOD